- ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
-
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
- -
-
-
- Aryl ureas as kinase inhibitors
-
This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VE
- -
-
-
- RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY
-
The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
- -
-
Page/Page column 29
(2008/12/08)
-
- TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS
-
The present invention provides compositions and methods for treating cancers ; which have acquired resistance to a KIT inhibitor by administering effective amounts of sorafenib.
- -
-
-
- DIARYL UREAS AND COMBINATIONS
-
The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I) : B-NH-C(O)-NH-L-M-L1-(Q)1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. Each Q is independently C(O)R4, C(O)OR4 and C(O)NR4R5; and L' is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.
- -
-
Page/Page column 45-46
(2008/06/13)
-
- TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS
-
The present invention provides compositions and methods for treating cancer with sorafenib, wherein the cancer that has acquired resistance to another therapeutic agent, such as kinase inhibitors. Sorafinb can also be used to treat cancers which have become refractory to other chemotherapeutic agents .
- -
-
Page/Page column 15-16
(2010/11/27)
-
- DIARYL UREAS WITH KINASE INHIBITING ACTIVITY
-
The present invention provides methods of using aryl ureas to treat diseases and conditions associated with signal transduction pathways comprising at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. The present invention also provides compositions and methods for identifying conditions and diseases which can be modulated with compounds of the present invention. These methods facilitate the selection of subjects who can be efficiently treated with compounds of the present invention. Additionally, the invention provides methods for monitoring subjects who have been administered a compound of the present invention.
- -
-
-
- Aryl ureas with angiogenisis inhibiting activity
-
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
- -
-
-
- Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
-
This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
- -
-
-
- Aryl ureas as kinase inhibitors
-
This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
- -
-
-